Low 25-hydroxyvitamin D levels are associated with vitiligo: a systematic review and meta-analysis

Photodermatology Photoimmunology and Photomedicine

Volumn 32, Issue 4, 2016, Pages 181-190

  Upala, Sikarin ^a,b   Sanguankeo, Anawin ^a,b  

^a Bassett Medical Center and Columbia University College of Physicians and Surgeons ^*  (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

cholecalciferol; meta analysis; pigmentation disorders; vitamin D; vitiligo

Indexed keywords

25 HYDROXYVITAMIN D; 25-HYDROXYVITAMIN D; VITAMIN D;

ARTICLE; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; HUMAN; META ANALYSIS; OBSERVATIONAL STUDY; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SUN EXPOSURE; SYSTEMATIC REVIEW; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; VITILIGO; ADULT; ANALOGS AND DERIVATIVES; BLOOD; FEMALE; MALE;

ADULT; FEMALE; HUMANS; MALE; VITAMIN D; VITILIGO;

EID: 84963823283     PISSN: 09054383     EISSN: 16000781     Source Type: Journal    
DOI: 10.1111/phpp.12241     Document Type: Article

References (36)

1. Giovannucci E, Liu Y, Rimm EB et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 2006; 98: 451–459.
2. Feskanich D, Ma J, Fuchs CS et al. Plasma vitamin D metabolites and risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 2004; 13: 1502–1508.
3. Zittermann A. Vitamin D and disease prevention with special reference to cardiovascular disease. Prog Biophys Mol Biol 2006; 92: 39–48.
4. Cantorna MT, Zhu Y, Froicu M, Wittke A. Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr 2004; 80(6 Suppl): 1717S–1720S.
5. Cantorna MT. Vitamin D and autoimmunity: is vitamin D status an environmental factor affecting autoimmune disease prevalence? Proc Soc Exp Biol Med 2000; 223: 230–233.
6. Marzano AV, Trevisan V, Eller-Vainicher C et al. Evidence for vitamin D deficiency and increased prevalence of fractures in autoimmune bullous skin diseases. Br J Dermatol 2012; 167: 688–691.
7. Aksu Cerman A, Sarikaya Solak S, Kivanc Altunay I. Vitamin D deficiency in alopecia areata. Br J Dermatol 2014;170:1299–1304.
8. Halder RM, Chappell JL. Vitiligo update. Semin Cutan Med Surg 2009; 28: 86–92.
9. Ongenae K, Van Geel N, Naeyaert JM. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res 2003; 16: 90–100.
10. Cho SB, Kim JH, Cho S, Park JM, Park YK, Oh SH. Vitiligo in children and adolescents: association with thyroid dysfunction. J Eur Acad Dermatol Venereol 2011; 25: 64–67.
11. Lips P, van Schoor NM, de Jongh RT. Diet, sun, and lifestyle as determinants of vitamin D status. Ann N Y Acad Sci 2014; 1317: 92–98.
12. Stroup DF, Berlin JA, Morton SC et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008–2012.
13. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25: 603–605.
14. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005; 20: 13.
15. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557–560.
16. Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 2001; 54: 1046–1055.
17. Sehrawat M, Arora TC, Chauhan A, Kar HK, Poonia A, Jairath V. Correlation of vitamin D levels with pigmentation in Vitiligo patients treated with NBUVB therapy. ISRN Dermatol 2014; 2014: 493213.
18. Saleh HM, Abdel Fattah NS, Hamza HT. Evaluation of serum 25-hydroxyvitamin D levels in vitiligo patients with and without autoimmune diseases. Photodermatol Photoimmunol Photomed 2013; 29: 34–40.
19. Li K, Shi Q, Yang L et al. The association of vitamin D receptor gene polymorphisms and serum 25-hydroxyvitamin D levels with generalized vitiligo. Br J Dermatol 2012; 167: 815–821.
20. Xu X, Fu WW, Wu WY. Serum 25-hydroxyvitamin D deficiency in Chinese patients with vitiligo: a case-control study. PLoS One 2012; 7: e52778.
21. Ustun I, Seraslan G, Gokce C et al. Investigation of vitamin D levels in patients with vitiligo vulgaris. Acta Dermatovenerologica Croatica 2014; 22: 110–113.
22. Khurrum H, AlGhamdi KM. The Relationship between the Serum Level of Vitamin D and Vitiligo: a Controlled Study on 300 Subjects. J Cutan Med Surg 2015; 20: 139–145
23. Adorini L, Penna G. Control of autoimmune diseases by the vitamin D endocrine system. Nat Clin Pract Rheumatol 2008; 4: 404–412.
24. Kriegel MA, Manson JE, Costenbader KH. Does vitamin D affect risk of developing autoimmune disease?: A systematic review. Semin Arthritis Rheum 2011; 40: 512–531.
25. Kumar J, Muntner P, Kaskel FJ, Hailpern SM, Melamed ML. Prevalence and associations of 25-hydroxyvitamin D deficiency in US children: NHANES 2001–2004. Pediatrics 2009; 124: e362–e370.
26. Silverberg JI, Silverberg AI, Malka E, Silverberg NB. A pilot study assessing the role of 25 hydroxy vitamin D levels in patients with vitiligo vulgaris. J Am Acad Dermatol 2010; 62: 937–941.
27. Lemire JM, Archer DC. 1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest 1991; 87: 1103–1107.
28. Mathieu C, Waer M, Laureys J, Rutgeerts O, Bouillon R. Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3. Diabetologia 1994; 37: 552–558.
29. Cantorna MT, Munsick C, Bemiss C, Mahon BD. 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr 2000; 130: 2648–2652.
30. Chiaverini C, Passeron T, Ortonne JP. Treatment of vitiligo by topical calcipotriol. J Eur Acad Dermatol Venereol 2002; 16: 137–138.
31. Travis LB, Silverberg NB. Calcipotriene and corticosteroid combination therapy for vitiligo. Pediatr Dermatol 2004; 21: 495–498.
32. Gamil H, Attwa E, Ghonemy S. Narrowband ultraviolet B as monotherapy and in combination with topical calcipotriol in the treatment of generalized vitiligo. Clin Exp Dermatol 2010; 35: 919–921.
33. Ameen M, Exarchou V, Chu AC. Topical calcipotriol as monotherapy and in combination with psoralen plus ultraviolet A in the treatment of vitiligo. Br J Dermatol 2001; 145: 476–479.
34. Goldinger SM, Dummer R, Schmid P, Burg G, Seifert B, Lauchli S. Combination of 308-nm xenon chloride excimer laser and topical calcipotriol in vitiligo. J Eur Acad Dermatol Venereol 2007; 21: 504–508.
35. Brozyna AA, Jozwicki W, Janjetovic Z, Slominski AT. Expression of vitamin D receptor decreases during progression of pigmented skin lesions. Hum Pathol 2011; 42: 618–631.
36. Birlea SA, Costin GE, Norris DA. Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation. Curr Drug Targets 2008; 9: 345–359.